Literature DB >> 29215383

Mood-Stabilizing Anticonvulsants, Spina Bifida, and Folate Supplementation: Commentary.

Neil Patel, Adele C Viguera, Ross J Baldessarini.   

Abstract

PURPOSE/
BACKGROUND: High risks of neural tube defects and other teratogenic effects are associated with exposure in early pregnancy to some anticonvulsants, including in women with bipolar disorder. METHODS/PROCEDURES: Based on a semistructured review of recent literature, we summarized findings pertaining to this topic. FINDINGS/
RESULTS: Valproate and carbamazepine are commonly used empirically (off-label) for putative long-term mood-stabilizing effects. Both anticonvulsants have high risks of teratogenic effects during pregnancy. Risks of neural tube defects (especially spina bifida) and other major malformations are especially great with valproate and can arise even before pregnancy is diagnosed. Standard supplementation of folic acid during pregnancy can reduce risk of spontaneous spina bifida, but not that associated with valproate or carbamazepine. In contrast, lamotrigine has regulatory approval for long-term use in bipolar disorder and appears not to have teratogenic effects in humans. IMPLICATIONS/
CONCLUSIONS: Lack of protective effects against anticonvulsant-associated neural tube defects by folic acid supplements in anticipation of and during pregnancy is not widely recognized. This limitation and high risks of neural tube and other major teratogenic effects, especially of valproate, indicate the need for great caution in the use of valproate and carbamazepine to treat bipolar disorder in women of child-bearing age.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29215383     DOI: 10.1097/JCP.0000000000000813

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  4 in total

1.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.

Authors:  Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; David J Bond; Benicio N Frey; Verinder Sharma; Benjamin I Goldstein; Soham Rej; Serge Beaulieu; Martin Alda; Glenda MacQueen; Roumen V Milev; Arun Ravindran; Claire O'Donovan; Diane McIntosh; Raymond W Lam; Gustavo Vazquez; Flavio Kapczinski; Roger S McIntyre; Jan Kozicky; Shigenobu Kanba; Beny Lafer; Trisha Suppes; Joseph R Calabrese; Eduard Vieta; Gin Malhi; Robert M Post; Michael Berk
Journal:  Bipolar Disord       Date:  2018-03-14       Impact factor: 6.744

2.  Comprehensive Measurements of Intrauterine and Postnatal Exposure to Lamotrigine.

Authors:  Michael Paulzen; Julia C Stingl; Marc Augustin; Helena Saßmannshausen; Cordula Franz; Gerhard Gründer; Georgios Schoretsanitis
Journal:  Clin Pharmacokinet       Date:  2019-04       Impact factor: 6.447

Review 3.  Clinical use of lithium salts: guide for users and prescribers.

Authors:  Leonardo Tondo; Martin Alda; Michael Bauer; Veerle Bergink; Paul Grof; Tomas Hajek; Ute Lewitka; Rasmus W Licht; Mirko Manchia; Bruno Müller-Oerlinghausen; René E Nielsen; Marylou Selo; Christian Simhandl; Ross J Baldessarini
Journal:  Int J Bipolar Disord       Date:  2019-07-22

4.  Diagnosis and management of individuals with Fetal Valproate Spectrum Disorder; a consensus statement from the European Reference Network for Congenital Malformations and Intellectual Disability.

Authors:  Jill Clayton-Smith; Rebecca Bromley; John Dean; Hubert Journel; Sylvie Odent; Amanda Wood; Janet Williams; Verna Cuthbert; Latha Hackett; Neelo Aslam; Heli Malm; Gregory James; Lena Westbom; Ruth Day; Edmund Ladusans; Adam Jackson; Iain Bruce; Robert Walker; Sangeet Sidhu; Catrina Dyer; Jane Ashworth; Daniel Hindley; Gemma Arca Diaz; Myfanwy Rawson; Peter Turnpenny
Journal:  Orphanet J Rare Dis       Date:  2019-07-19       Impact factor: 4.123

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.